Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
2.33%
↓ 76% below average
Average (39q)
9.90%
Historical baseline
Range
High:129.74%
Low:-57.85%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 2.33% |
| Q2 2025 | -7.18% |
| Q1 2025 | 41.81% |
| Q4 2024 | -4.82% |
| Q3 2024 | 2.04% |
| Q2 2024 | 19.89% |
| Q1 2024 | 15.93% |
| Q4 2023 | -3.31% |
| Q3 2023 | -2.47% |
| Q2 2023 | 4.52% |
| Q1 2023 | 18.22% |
| Q4 2022 | 9.56% |
| Q3 2022 | -20.75% |
| Q2 2022 | 32.97% |
| Q1 2022 | 16.93% |
| Q4 2021 | -5.72% |
| Q3 2021 | 23.93% |
| Q2 2021 | 2.19% |
| Q1 2021 | 9.75% |
| Q4 2020 | -3.47% |
| Q3 2020 | -14.59% |
| Q2 2020 | 38.77% |
| Q1 2020 | 5.19% |
| Q4 2019 | 22.35% |
| Q3 2019 | -26.58% |
| Q2 2019 | 63.66% |
| Q1 2019 | -3.60% |
| Q4 2018 | 10.22% |
| Q3 2018 | -4.07% |
| Q2 2018 | -24.43% |
| Q1 2018 | 91.09% |
| Q4 2017 | 14.03% |
| Q3 2017 | 2.72% |
| Q2 2017 | -57.85% |
| Q1 2017 | 129.74% |
| Q4 2016 | 7.84% |
| Q3 2016 | -22.04% |
| Q2 2016 | 12.38% |
| Q1 2016 | 9.60% |
| Q4 2015 | -10.57% |